The LEVEL Phase 3 readout in August 2026 is a binary event for TENX. With >90% power on the primary endpoint and no approved therapy for PH-HFpEF, positive data could drive a 2-3x re-rating; negative data would likely be catastrophic. Traders should position for high volatility into the ESC presentation on August 29, 2026.
Price Chart
Executive Summary
Tenax Therapeutics announced that Phase 3 LEVEL trial results for TNX-103 (oral levosimendan) in PH-HFpEF will be presented at the ESC Congress in late August 2026. The company expects to report topline data in August, with a database lock and statistical analysis proceeding in the weeks ahead. This is a binary catalyst event for a single-asset Phase 3 biotech — the stock will move sharply on the data readout.
Key Facts
- Phase 3 LEVEL trial results for TNX-103 (oral levosimendan) in PH-HFpEF will be presented at ESC Congress August 28-31, 2026 in Munich.
- Topline data expected in August 2026; database lock and statistical analysis proceeding in the weeks ahead.
- Trial enrolled over 230 patients; BSSR in Dec 2025 showed >90% power to detect a 25-meter change in 6MWD primary endpoint.
- PH-HFpEF is the most prevalent form of pulmonary hypertension globally with no approved product to date.
- Tenax owns global rights to develop and commercialize levosimendan for PH-HFpEF.
Financial Impact
Binary catalyst — positive data could unlock a multi-billion-dollar market (no approved therapy for PH-HFpEF); negative data would likely destroy most of the $353M market cap.
Risk Factors
- Phase 3 failure — negative or inconclusive topline data would likely destroy most of the $353M market cap.
- Data delay — if database lock or analysis slips past the ESC deadline, the stock could drift lower on uncertainty.
- Competing therapies or trial design issues (e.g., placebo effect, site variability) could muddy results.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3321224 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.76 (+29.41%) |
Oct 13, 2026 14d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.76 (+10.00%) |
Oct 9, 2026 17d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.76 (−3.83%) |
Oct 8, 2026 18d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.76 (−5.88%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.76 (−7.37%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.76 (−17.37%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.76 (−4.35%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.76 (+28.00%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.76 (+28.00%) |
Jul 31, 2026 12w ago | 8-K | $13.70 $13.44 | ▼ −1.90% | ▼ −5.41% | $1.76 (−87.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers